Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Evome Medical Technologies Provides Market Update

In This Article:

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is providing an update to shareholders today.

As important background:

Evome generates revenue from three main revenue lines:

  1. DaMar”. This a business-to-business revenue line. Located in California, DaMar Plastics Manufacturing, Inc. (“DaMar”) offers contract manufacturing to a highly concentrated group of customers that then sell those products under their own brand name.

  2. Biodex”. Biodex Medical Systems, Inc. (“Biodex”) is a branded medical device business with approximately 50% of revenue originating from international distributors and the other 50% from domestic dealers.

  3. The Tables Business”. This a business-to-business revenue line of Biodex. This business unit is co-located in Biodex’s factory in New York. It offers contract manufacturing to only one customer that then sells those products under their own brand name.

Business Update:

  1. Input costs expected to rise: As for input costs, each business line may be subject to increases in raw material costs caused by potential tariffs. Additionally, Biodex expects to be subject to retaliatory tariffs on the sale of its products outside the United States. Therefore, Biodex is working to understand the effect on prices to both domestic and international customers. Biodex plans to work with customers given the impacts of these potential price increases and their effect upon demand, cash flow and the value of each business line.

  2. Asset-based loan lender exits: The Company’s asset-based loan (“ABL”) provider has notified Evome that it will no longer continue lending to Evome’s subsidiaries. The total ABL debt has been reduced from $6,537,209 on March 31, 2024 to the current ABL debt level of $2,9049,634 as of March 27, 2025. As a result, the total balance has fallen below the minimum debt level requirement. While the ABL lender is working with the Company and its subsidiaries to ensure a smooth transition as it retires the ABL debt, all business units are expected to face a cash flow challenge through this period. The Company has negligible working capital currently.

  3. New management: The Company has entrusted a new management team to navigate through these challenges. Michael Seckler (CEO and a director of the Company), Wanye Anderson (a director of the Company), Lana Newishy (a director of the Company) and Bill Garbarini (COO) have resigned, and Chris Heath, a recently appointed director of the Company, has been appointed Interim CEO through this transition period. Kenneth Kashkin, MD, will remain on the Board of Directors as Vice-Chairman.

  4. No funds for audit: Given the current financial condition of the Company, including its current cash position, the reduction of the ABL and the potential of negative impacts of possible tariff policy, the Company does not currently have excess funds to pay for the year end audit as it will use all funds to continue manufacturing and shipping products to customers. It therefore expects to miss the deadline of April 30, 2025 (the “Filing Deadline”) to file the Company’s audited annual financial statements and management discussion & analysis for the financial year ended December 31, 2024, and the CEO and CFO certificates, all as required by National Instrument 51-102 - Continuous Disclosure Obligations and National Instrument 52-109 - Certification of Disclosure in Issuers’ Annual and Interim Filings (collectively, the “Documents”). As a consequence, the Company anticipates the imposition by the British Columbia Securities Commission of a Failure-to-File Cease Trade Order (“FFCTO”). There is no other reason known to management preventing the completion of the audit other than a lack of available funds. Accordingly, the Company is making efforts to complete an audit and file the Documents as soon as is financially feasible.

  5. Customers: Biodex has a back log of orders of over $6,228,854 as of May 27, 2025 from existing customers that Biodex intends to fulfill. DaMar and “The Tables” business continue to operate and ship products to their respective customers.

  6. DaMar Sale: As announced on May 30, 2024, DaMar is actively being marketed for sale.